LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD.

Andere Sprachen Luoxin Pharmaceuticals Group Stock Co., Ltd.

Aktien

002793

CNE1000026S7

002793

Schlusskurs Shenzhen S.E. Andere Börsenplätze 00:00:00 07.06.2024			% 5 Tage	% 1. Jan.
4.41 ^CNY	+1.38%		-8.12%	-17.72%

26.04.	Luoxin Pharmaceuticals Group Stock Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
08.03.	Luoxin Pharma erhält Recht zur Nutzung der fäkalen Mikrobiota-Transplantationstechnologie von Shenzhen Shishijijun Biotechnology	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26.04.
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology	08.03.
Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024.	19.02.
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback announced on February 2, 2024, has closed with 26,027,861 shares, representing 2.39% for CNY 99.99 million.	08.02.
Luoxin Pharmaceuticals Group Stock Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	01.02.
Luoxin Pharmaceuticals Group Stock Co., Ltd. authorizes a Buyback Plan.	01.02.
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial	29.01.
Two Luoxin Pharma Drugs Selected in China’s National Drug Procurement Program	17.11.
Luoxin Health Technology Development Co., Ltd. announced that it has received CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.	17.11.
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27.10.23
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023	23.10.23
Luoxin Pharmaceuticals Group Stock Co., Ltd. agreed to acquire additional unknown stake in Luoxin Health Technology Development Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP) and Deyi Investment Management Co., Ltd. for CNY 1.	14.10.23
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.	13.10.23
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28.08.23
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27.04.23
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27.04.23
Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Li Meng as Non-Independent Directors	01.02.23
Luoxin Pharmaceuticals' Injection Passes Regulatory Consistency Evaluation	11.01.23
Luoxin Pharmaceuticals Gets Regulatory Nod for Anti-Baterial Infection Drug	28.12.22
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28.10.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Luoxin Pharmaceuticals Group Stock Co., Ltd.

Aktien

002793

CNE1000026S7

002793

Andere Sprachen

Filter